---
title: "Cost evaluation in head and neck cancer clinical trials: Implications for high-value care"
collection: publications
permalink: /publications/collins2025cost
excerpt: 'Head and neck cancer (HNC) patients face some of the highest financial burdens of all cancer types due to complex, long-term treatments. However, this study of over 2,000 HNC clinical trials found that only 3.3% included cost as an outcome, and nearly all have yet to report results. This is lower than in many other cancers, despite rising healthcare costs and the importance of cost-effective care. These findings highlight a need for more consistent inclusion of cost data in trials to better guide treatment decisions and support patients facing financial hardship.'
date: 2025-05-10
venue: â€˜American Journal of Otolaryngology'
clink: 'https://doi.org/10.1016/j.amjoto.2025.104655 '
purl: '/files/collins2025cost.pdf'
citation: 'Collins RS, Lee IA, <b>Habib DRS</b>, Garner DC, Johnson DB, Patel PN, Topf MC. Cost evaluation in head and neck cancer clinical trials: Implications for high-value care. <i>Am J Otolaryngol</i>. 2025;46(5):104655. doi:10.1016/j.amjoto.2025.104655'
---
[Download PDF here](http://danielrshabib.github.io/files/collins2025cost.pdf)

Head and neck cancer (HNC) patients face some of the highest financial burdens of all cancer types due to complex, long-term treatments. However, this study of over 2,000 HNC clinical trials found that only 3.3% included cost as an outcome, and nearly all have yet to report results. This is lower than in many other cancers, despite rising healthcare costs and the importance of cost-effective care. These findings highlight a need for more consistent inclusion of cost data in trials to better guide treatment decisions and support patients facing financial hardship.
